紫衫醇脂质体联合卡铂和替雷利珠单抗在肺鳞癌患者中的应用研究  

Study on the application of paclitaxel liposome combined with carboplatin and tirellizumab in patients with lung squamous cell carcinoma

作　　者：曾奕蜚 蒋剑 唐丽云 ZENG Yi-fei;JIANG Jian;TANG Li-yun(Department of Oncology,The Third People’s Hospital of Yongzhou,Yongzhou 425000,China)

机构地区：[1]永州市第三人民医院肿瘤科,湖南永州425000

出　　处：《中国处方药》2024年第5期125-128,共4页Journal of China Prescription Drug

摘　　要：目的探究紫衫醇脂质体联合卡铂和替雷利珠单抗在肺鳞癌患者中的应用效果。方法选取2021年~2022年收治的50例肺鳞癌患者,按照随机数字法分为对照组(n=25)和观察组(n=25),其中对照组采用紫衫醇脂质体联合卡铂治疗,观察组在对照组的基础上采用替雷利珠单抗治疗。比较两组患者肿瘤标志物水平、生活质量及毒副反应,评估患者临床疗效。结果观察组总有效率高于对照组(P<0.05);治疗后,两组血清鳞状上皮细胞癌抗原(SCC)、细胞角蛋白19的可溶性片段(CYFRA21-1)、糖类抗原125(CA125)及癌胚抗原(CEA)水平均降低(P<0.05),且观察组低于对照组(P<0.05);治疗后,两组社会/家庭生活、日常生活、活动能力、情绪、其他因素及总分均升高(P<0.05),且观察组高于对照组(P<0.05);与对照组相比,观察组未明显增加毒副反应(P>0.05)。结论肺鳞癌患者采用紫衫醇脂质体联合卡铂和替雷利珠单抗治疗效果显著,可控制血清肿瘤标志水平,改善患者生活质量,且安全性相对有保障。Objective To investigate the application of paclitaxel liposome combined with carboplatin and tirellizumab in patients with lung squamous cell carcinoma.Methods Fifty patients with lung squamous cell carcinoma enrolled in a hospital from 2021 to 2022 were selected and divided into the control group(n=25)and the observation group(n=25)according to random number method.The control group was treated with paclitaxel liposome combined with carboplatin,and the observation group was treated with tirilizumab on the basis of the control group.The tumor marker levels,quality of life,and toxic and side effects of the two groups were compared,and the clinical efficacy of the patients was evaluated.Results The total effective rate of observation group was higher than that of the control group(P<0.05).After treatment,serum levels of SCC,CYFRA21-1,CA125 and CEA in the two groups were decreased(P<0.05),and observation group was lower than control group(P<0.05).After treatment,the social/family life,daily life,activity ability,emotion,other factors and total scores of both groups were increased(P<0.05),and the observation group was higher than those of the control group(P<0.05).Compared with the control group,the toxic and side effects were not significantly increased in the observation group(P>0.05).Conclusion The treatment of lung squamous cell carcinoma patients with paclitaxel liposome combined with carboplatin and tirellizumab is effective,can control the level of serum tumor markers,improve the quality of life,and the safety is relatively guaranteed.

关 键 词：肺鳞癌 紫衫醇脂质体 替雷利珠单抗 卡铂 应用研究 

分 类 号：R734.2[医药卫生—肿瘤]